Our trial of ondansetron as a treatment for hallucinations in Parkinson's is restarting Date 22 November 2024
New device improves Parkinson’s symptoms Date 25 July 2019 Researchers have shown that an ‘easy to use’ portable stimulation headset may be able to reduce both motor and non-motor symptoms of Parkinson’s.
Welfare is unfair, says new report Date 16 July 2019 A new report from the Disability Benefits Consortium shows how changes to the benefits system have had a devastating impact on disabled people.
New research puts serotonin at the heart of Parkinson’s Date 20 June 2019 In a seminal research paper, published in Lancet Neurology, researchers from King’s College London have used brain scans to uncover early changes in the brain that may happen years before the symptoms of Parkinson's appear.
HYPE protein found to target alpha-synuclein Date 19 June 2019 Researchers in the US have identified a protein in the brain that may reduce the spread of the toxic alpha-synuclein protein in Parkinson's.
Existing drugs may help the brain protect itself against Parkinson's Date 5 June 2019 Researchers at King's College London have investigated the properties of over 1,000 approved drugs to identify 2 with potential for Parkinson's.
New mouse model highlights promising potential drug for slowing Parkinson’s Date 4 June 2019 The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Repurposed drug enters clinical trial for Lewy body dementia Date 3 June 2019 Researchers in the US have launched a clinical trial to test a drug with the potential to slow the progression of Lewy body dementia.
Shaping the volunteer awards Date 31 May 2019 Our values shape the new volunteer awards, so we take a look at some of the volunteers showcasing them.
New study suggests that having bipolar disorder increases the risk of Parkinson's Date 28 May 2019 People with bipolar disorder are almost 7 times more likely to develop Parkinson's than those without the condition, according to new research published in the journal Neurology.
Blood pressure drug fails in phase 3 Parkinson's trial Date 8 May 2019 The STEADY-PD clinical trial has failed to show that isradipine is an effective treatment to slow or stop progression in early Parkinson's.
